通过谷氨胺对抗作用准胰腺癌的代谢依赖性
Joel Encarnación-Rosado1,2, Albert S W Sohn1,2, Douglas E Biancur1,2
1Perlmutter Cancer Center, New York University Grossman School of Medicine, New York, NY, USA.
Nature cancer
|October 9, 2023
概括
在胰腺癌中用DON或其前药DRP-104准谷氨胺代谢导致了代谢危机. 将DRP-104与ERK抑制剂相结合,在胰腺管道腺癌模型中显著改善了生存率.
科学领域:
- 在瘤学瘤学.
- 代谢途径 代谢途径
- 癌细胞生物学 癌细胞生物学
背景情况:
- 胰腺管腺癌 (PDAC) 依赖谷氨酸 (Gln) 进行增殖和氧化还原平衡.
- 以前试图抑制Gln代谢的尝试面临着由于快速代谢重编程和治疗耐药性而面临的挑战.
研究的目的:
- 在PDAC中研究谷氨酸胺抗剂的疗效.
- 探索组合疗法,以改善PDAC的治疗结果.
主要方法:
- 在PDAC细胞的体外治疗中使用6-diazo-5-oxo-L-norleucine (DON).
- 在PDAC模型中使用sirpiglenastat (DRP-104),一种DON前药物的体内研究.
- 细胞外信号调节激酶 (ERK) 信号通路的分析.
- 使用DRP-104和美丁尼 (ERK抑制剂) 的组合治疗.
主要成果:
- 在实验室中,DON在PDAC细胞中引起了显著的代谢危机.
- 在体内,DRP-104表现出严重的瘤生长抑制.
- ERK信号被确定为由Gln对抗激活的补偿机制.
- 在合成PDAC模型中,与DRP-104和美丁尼的联合治疗显著增加了存活率.
结论:
- 向谷氨胺代谢是PDAC的潜在治疗策略.
- 涉及谷氨胺对抗和ERK通路抑制的组合疗法可能会提高PDAC的治疗疗效.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Adaptive Mechanisms in Cancer Cells
5.8K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K


